These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 35762079)
1. Comparative effects of fentanyl versus morphine on platelet inhibition induced by ticagrelor in patients with ST-segment elevation myocardial infarction: Full results of the PERSEUS randomized trial. Iglesias JF; Valgimigli M; Carbone F; Lauriers N; Masci PG; Degrauwe S Cardiol J; 2022; 29(4):591-600. PubMed ID: 35762079 [TBL] [Abstract][Full Text] [Related]
2. Influence of intravenous fentanyl compared with morphine on ticagrelor absorption and platelet inhibition in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the PERSEUS randomized trial. Degrauwe S; Roffi M; Lauriers N; Muller O; Masci PG; Valgimigli M; Iglesias JF Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):158-163. PubMed ID: 30101278 [TBL] [Abstract][Full Text] [Related]
3. Differential impact of fentanyl and morphine doses on ticagrelor-induced platelet inhibition in ST-segment elevation myocardial infarction: a subgroup analysis from the PERSEUS randomized trial. Garin D; Degrauwe S; Carbone F; Musayeb Y; Lauriers N; Valgimigli M; Iglesias JF Front Cardiovasc Med; 2024; 11():1324641. PubMed ID: 38628315 [TBL] [Abstract][Full Text] [Related]
4. Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation. Franchi F; Rollini F; Cho JR; Bhatti M; DeGroat C; Ferrante E; Dunn EC; Nanavati A; Carraway E; Suryadevara S; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ JACC Cardiovasc Interv; 2015 Sep; 8(11):1457-1467. PubMed ID: 26404199 [TBL] [Abstract][Full Text] [Related]
5. The MOVEMENT Trial. Holm M; Tornvall P; Henareh L; Jensen U; Golster N; Alström P; Santos-Pardo I; Witt N; Fedchenko N; Venetsanos D; Beck O; van der Linden J J Am Heart Assoc; 2019 Jan; 8(2):e010152. PubMed ID: 30636504 [TBL] [Abstract][Full Text] [Related]
6. P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study. Silvain J; Storey RF; Cayla G; Esteve JB; Dillinger JG; Rousseau H; Tsatsaris A; Baradat C; Salhi N; Hamm CW; Lapostolle F; Lassen JF; Collet JP; Ten Berg JM; Van't Hof AW; Montalescot G Thromb Haemost; 2016 Aug; 116(2):369-78. PubMed ID: 27196998 [TBL] [Abstract][Full Text] [Related]
7. Effects of Fentanyl Versus Morphine on Ticagrelor-Induced Platelet Inhibition in Patients With ST-Segment Elevation Myocardial Infarction: The PERSEUS Randomized Trial. Iglesias JF; Valgimigli M; Carbone F; Lauriers N; Giorgio Masci P; Degrauwe S Circulation; 2020 Dec; 142(25):2479-2481. PubMed ID: 33347326 [No Abstract] [Full Text] [Related]
8. Fentanyl Delays the Platelet Inhibition Effects of Oral Ticagrelor: Full Report of the PACIFY Randomized Clinical Trial. Ibrahim K; Shah R; Goli RR; Kickler TS; Clarke WA; Hasan RK; Blumenthal RS; Thiemann DR; Resar JR; Schulman SP; McEvoy JW Thromb Haemost; 2018 Aug; 118(8):1409-1418. PubMed ID: 29972861 [TBL] [Abstract][Full Text] [Related]
9. Impact of opioids on P2Y12 receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial. Tavenier AH; Hermanides RS; Ottervanger JP; Tolsma R; van Beurden A; Slingerland RJ; Ter Horst PGJ; Gosselink ATM; Dambrink JE; van Leeuwen MAH; Roolvink V; Kedhi E; Klungel OH; Belitser SV; Angiolillo DJ; Pustjens T; Rasoul S; Gho B; Stein M; Ruiters L; van 't Hof AWJ Eur Heart J Cardiovasc Pharmacother; 2022 Jan; 8(1):4-12. PubMed ID: 32730628 [TBL] [Abstract][Full Text] [Related]
10. Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study. Adamski P; Sikora J; Laskowska E; Buszko K; Ostrowska M; Umińska JM; Sikora A; Skibińska N; Sobczak P; Adamska U; Rość D; Kubica A; Paciorek P; Marszałł MP; Navarese EP; Gorog DA; Kubica J PLoS One; 2017; 12(10):e0186013. PubMed ID: 29023473 [TBL] [Abstract][Full Text] [Related]
11. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. Parodi G; Valenti R; Bellandi B; Migliorini A; Marcucci R; Comito V; Carrabba N; Santini A; Gensini GF; Abbate R; Antoniucci D J Am Coll Cardiol; 2013 Apr; 61(15):1601-6. PubMed ID: 23500251 [TBL] [Abstract][Full Text] [Related]
12. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341 [TBL] [Abstract][Full Text] [Related]
13. Ticagrelor Pharmacokinetics and Pharmacodynamics in Chinese Patients with STEMI and NSTEMI Without Opioid Administration. Wang Y; Wu H; Chen Y; Wang Q; Qian J; Ge J Adv Ther; 2020 Oct; 37(10):4220-4232. PubMed ID: 32770531 [TBL] [Abstract][Full Text] [Related]
14. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985 [TBL] [Abstract][Full Text] [Related]
15. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Kubica J; Adamski P; Ostrowska M; Sikora J; Kubica JM; Sroka WD; Stankowska K; Buszko K; Navarese EP; Jilma B; Siller-Matula JM; Marszałł MP; Rość D; Koziński M Eur Heart J; 2016 Jan; 37(3):245-52. PubMed ID: 26491112 [TBL] [Abstract][Full Text] [Related]
16. Effects of intravenous lysine acetylsalicylate versus oral aspirin on platelet responsiveness in patients with ST-segment elevation myocardial infarction: the ECCLIPSE-STEMI trial. Vivas D; Jiménez JJ; Martín-Asenjo R; Bernardo E; Ortega-Pozzi MA; Gómez-Polo JC; Moreno G; Vilacosta I; Pérez-Villacastín J; Fernández-Ortiz A J Thromb Thrombolysis; 2023 Feb; 55(2):203-210. PubMed ID: 36480147 [TBL] [Abstract][Full Text] [Related]
17. Ticagrelor pharmacokinetics and pharmacodynamics in patients with NSTEMI after a 180-mg loading dose. Holm M; Tornvall P; Westerberg J; Rihan Hye S; van der Linden J Platelets; 2017 Nov; 28(7):706-711. PubMed ID: 28150519 [TBL] [Abstract][Full Text] [Related]
18. Negative Impact of ST-Segment Elevation Myocardial Infarction and Morphine Dose on Ticagrelor Uptake and Pharmacodynamics: A Population PK/PD Analysis of Pooled Individual Participant Data. Konecki C; Holm M; Djerada Z Clin Pharmacokinet; 2023 Jun; 62(6):905-920. PubMed ID: 37097605 [TBL] [Abstract][Full Text] [Related]
19. Design and Rationale of the APELOT Trial: A Randomized, Open-Label, Multicenter, Phase IV Study to Evaluate the Antiplatelet Effect of Different Loading Dose of Ticagrelor in Patients With Non-ST Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Liu HL; Wei YJ; Jin ZG; Zhang J; Ding P; Yang SL; Luo JP; Ma DX; Liu Y; Han W Medicine (Baltimore); 2016 May; 95(22):e3756. PubMed ID: 27258504 [TBL] [Abstract][Full Text] [Related]
20. Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine. Lapostolle F; Van't Hof AW; Hamm CW; Stibbe O; Ecollan P; Collet JP; Silvain J; Lassen JF; Heutz WMJM; Bolognese L; Cantor WJ; Cequier A; Chettibi M; Goodman SG; Hammett CJ; Huber K; Janzon M; Merkely B; Storey RF; Ten Berg J; Zeymer U; Licour M; Tsatsaris A; Montalescot G; Am J Cardiovasc Drugs; 2019 Apr; 19(2):173-183. PubMed ID: 30353444 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]